pubmed.ncbi.nlm.nih.gov

Cannabinoid pharmacology: the first 66 years - PubMed

Cannabinoid pharmacology: the first 66 years

Roger G Pertwee. Br J Pharmacol. 2006 Jan.

Abstract

Research into the pharmacology of individual cannabinoids that began in the 1940s, several decades after the presence of a cannabinoid was first detected in cannabis, is concisely reviewed. Also described is how this pharmacological research led to the discovery of cannabinoid CB(1) and CB(2) receptors and of endogenous ligands for these receptors, to the development of CB(1)- and CB(2)-selective agonists and antagonists and to the realization that the endogenous cannabinoid system has significant roles in both health and disease, and that drugs which mimic, augment or block the actions of endogenously released cannabinoids must have important therapeutic applications. Some goals for future research are identified.

PubMed Disclaimer

Figures

Figure 1
Figure 1

The structures of five plant cannabinoids (phytocannabinoids), Δ9-tetrahydrocannabinol (Δ9-THC), Δ8-THC, cannabidiol (CBD), cannabinol (CBN) and Δ9-tetrahydrocannabivarin (Δ9-THCV), and of two synthetic cannabinoids, Δ6a,10a-THC and synhexyl.

Figure 2
Figure 2

The structures of two endocannabinoids, anandamide and 2-arachidonoyl glycerol.

Figure 3
Figure 3

Potential clinical strategies for the management of disorders in which an increased production of anandamide may lead to a reduction in the intensity of unwanted signs and symptoms (reviewed in Pertwee 2005c). These strategies rely on augmentation of apparent anandamide-mediated protective effects through inhibition of the cellular uptake of anandamide, through inhibition of its intracellular metabolism by fatty acid amide hydrolase or through allosteric enhancement of anandamide-induced CB1 receptor activation.

Similar articles

Cited by

References

    1. AGURELL S., HALLDIN M., LINDGREN J.-E., OHLSSON A., WIDMAN M., GILLESPIE H., HOLLISTER L. Pharmacokinetics and metabolism of Δ1-tetrahydrocannabinol and other cannabinoids with emphasis on man. Pharmacol. Rev. 1986;38:21–43. - PubMed
    1. BROWN A., WISE A.2003Identification of modulators of gpr55 activityUS Patent Document Number 20030113814 at http://appft1.uspto.gov/netahtml/PTO/search-bool.html .
    1. DEVANE W.A., HANUS L., BREUER A., PERTWEE R.G., STEVENSON L.A., GRIFFIN G., GIBSON D., MANDELBAUM A., ETINGER A., MECHOULAM R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 1992;258:1946–1949. - PubMed
    1. DI MARZO V., DE PETROCELLIS L., BISOGNO T.2005The biosynthesis, fate and pharmacological properties of endocannabinoids Cannabinoids. Handbook of Experimental Pharmacologyed. Pertwee, R.G. vol. 168, pp. 147–185.Heidelburg: Springer-Verlag - PubMed
    1. ELSOHLY M.A.2002Chemical constituents of cannabis Cannabis and Cannabinoids. Pharmacology, Toxicology and Therapeutic Potentialeds. Grotenhermen, F. & Russo, E. pp. 27–36.New York: Haworth Press Inc

Publication types

MeSH terms

Substances